A small device implanted just beneath the skin, roughly the size of a large postage stamp and weighing about two grams, kept ...
The FDA has approved Awiqli, the first once‑weekly long‑acting basal insulin, for adults with type 2 diabetes, which offers ...
“Insulin injections remain a daily burden for many patients,” said Shingo Ito, an associate professor at Kumamoto University ...
Some patients with type 2 diabetes will be able to switch from daily insulin injections to this first-of-its-kind once-weekly ...
For over a century, scientists have chased the dream of insulin pills, but the digestive system kept destroying the drug ...
CNW/ -- (SSE: 603087) today announced that two pivotal phase 3 clinical trials, SUPER-1 and SUPER-2, evaluating ...
March 26 (Reuters) - The U.S. Food and Drug Administration has approved Novo Nordisk's insulin injection, Awiqli, to control ...
“Insulin injections remain a daily burden for many patients,” said Associate Professor Shingo Ito. “Our peptide-based ...
Please provide your email address to receive an email when new articles are posted on . A group of experts updated the FITTER insulin injection recommendations for the first time since 2016. The ...
Researchers in Japan have reported a significant step in the long‑standing scientific effort to develop an insulin medication ...
The primary factor behind diabetes is that your body may not make enough insulin (type 1 diabetes) or it fails to respond to the insulin your pancreas releases, which is known as insulin resistance ...
(1,2) "Awiqli (R) is an important new option that meets a real need as the first FDA-approved, once-weekly basal insulin for adult patients with type 2 diabetes. It's helping to reframe what basal ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results